A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

3期 进行中（已停止招募） NCT05123703

摘要

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.

Protocol-defined Annualized Relapse Rate (ARR)

Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks) · relapses per patient-year

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
• A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche

全部试验